Cognition Therapeutics (NASDAQ:CGTX) Cut to Neutral at Cantor Fitzgerald

Cantor Fitzgerald lowered shares of Cognition Therapeutics (NASDAQ:CGTX) from an overweight rating to a neutral rating in a research note released on Tuesday, Marketbeat Ratings reports.

Other equities research analysts have also issued reports about the company. Rodman & Renshaw reiterated a buy rating and set a $14.00 price objective on shares of Cognition Therapeutics in a research note on Tuesday, July 2nd. Chardan Capital started coverage on Cognition Therapeutics in a report on Thursday, June 6th. They set a buy rating and a $11.00 target price on the stock. Finally, HC Wainwright started coverage on Cognition Therapeutics in a report on Wednesday, May 29th. They set a buy rating and a $10.00 target price on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $8.67.

Cognition Therapeutics Trading Down 10.0 %

NASDAQ:CGTX opened at $0.90 on Tuesday. Cognition Therapeutics has a 12 month low of $0.90 and a 12 month high of $2.95. The stock has a 50 day moving average of $1.90 and a two-hundred day moving average of $1.99. The firm has a market cap of $36.05 million, a P/E ratio of -0.98 and a beta of 1.47.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, research analysts forecast that Cognition Therapeutics will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CGTX. Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics in the first quarter valued at approximately $47,000. Sigma Planning Corp acquired a new position in Cognition Therapeutics in the fourth quarter valued at approximately $53,000. Levin Capital Strategies L.P. acquired a new position in Cognition Therapeutics in the first quarter valued at approximately $55,000. Bangor Savings Bank lifted its holdings in Cognition Therapeutics by 41.6% in the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new position in Cognition Therapeutics in the fourth quarter valued at approximately $102,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.